High LRFN4 expression correlated with poor prognosis in gastric cancer (FP, P = 0.0011; PPS, P = 0.00018), ovarian cancer (RFS, P = 0.045), colon cancer (relapse-free survival, P = 0.0019), and lung cancer (P = 0.00026) (Figure 7). Here, LRFN4 is linked to gastric cancer.